APA (7th ed.) Citation

S, K., S, S., T, d. W., F, M., R, W., L, R., . . . RA, Z. (1996). Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: An analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups. Bone marrow transplantation, 17(6), 993.

Chicago Style (17th ed.) Citation

S, Keating, et al. "Prognostic Factors of Patients with Acute Myeloid Leukemia (AML) Allografted in First Complete Remission: An Analysis of the EORTC-GIMEMA AML 8A Trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne Dell' Adulto (GIMEMA) Leukemia Cooperative Groups." Bone Marrow Transplantation 17, no. 6 (1996): 993.

MLA (9th ed.) Citation

S, Keating, et al. "Prognostic Factors of Patients with Acute Myeloid Leukemia (AML) Allografted in First Complete Remission: An Analysis of the EORTC-GIMEMA AML 8A Trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne Dell' Adulto (GIMEMA) Leukemia Cooperative Groups." Bone Marrow Transplantation, vol. 17, no. 6, 1996, p. 993.